DOTA-K(sCy5)-pADA-fQWAVGH-NHCH[CH2CH(CH3)2]2

DOTA-K(sCy5)-pADA-fQWAVGH-NHCH[CH2CH(CH3)2]2 (also known as compound 14 or probe 14) is a bimodal (nuclear/optical) imaging probe developed by Erasmus MC for the pre- and intraoperative visualization of gastrin-releasing peptide receptor (GRPR)-expressing solid tumors, such as prostate cancer. The probe is based on the backbone of the established GRPR antagonist NeoB (formerly NeoBOMB1). It incorporates a DOTA chelator for radiolabeling (e.g., with indium-111) to enable preoperative SPECT/CT imaging, and a sulfo-cyanine 5 (sCy5) fluorescent dye for intraoperative surgical guidance. The probe features a rigid pADA linker in its backbone, which contributes to favorable tumor retention and targeting properties.

Other names

[111In]In-14[111In]In-compound 14[111In]In-DOTA-K(sCy5)-pADA-fQWAVGH-NHCH[CH2CH(CH3)2]2[111In]In-probe 14indium-111 labeled probe 14indium111 labeled probe 14indium 111 labeled probe 14